High-flow nasal oxygen versus conventional oxygen therapy in patients with COVID-19 pneumonia and mild hypoxaemia: a randomised controlled trial
Rationale In patients with COVID-19 pneumonia and mild hypoxaemia, the clinical benefit
of high-flow nasal oxygen (HFNO) remains unclear. We aimed to examine whether HFNO …
of high-flow nasal oxygen (HFNO) remains unclear. We aimed to examine whether HFNO …
[HTML][HTML] Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
…, MT Busceti, MF Caiaffa, R Campisi… - Frontiers in …, 2023 - frontiersin.org
Background The efficacy of dupilumab as biological treatment of severe asthma and chronic
rhinosinusitis with nasal polyps (CRSwNP) depends on its ability to inhibit the …
rhinosinusitis with nasal polyps (CRSwNP) depends on its ability to inhibit the …
[HTML][HTML] Misdiagnosis of asthma and COPD and underuse of spirometry in primary care unselected patients
BACKGROUND The diagnosis of both asthma and chronic obstructive pulmonary disease (COPD)
consists of a combination of classical symptoms and signs, and the evidence of …
consists of a combination of classical symptoms and signs, and the evidence of …
[HTML][HTML] Practical considerations for spirometry during the COVID-19 outbreak: Literature review and insights
Background As the Coronavirus disease 2019 (COVID-19) is spreading worldwide, countries
are dealing with different phases of the pandemic. Lately, scientific evidence has been …
are dealing with different phases of the pandemic. Lately, scientific evidence has been …
Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study
…, G Scioscia, G Spadaro, R Campisi… - The Journal of Allergy …, 2021 - Elsevier
Background Chronic rhinosinusitis with nasal polyps (CRSwNP) affects around 60% of
patients with severe eosinophilic asthma (SEA). Benralizumab was recently approved for SEA …
patients with severe eosinophilic asthma (SEA). Benralizumab was recently approved for SEA …
[HTML][HTML] Reliability and usefulness of a rapid IgM‐IgG antibody test for the diagnosis of SARS-CoV-2 infection: A preliminary report.
…, R Manuele, C Crimi, MP Pistorio, R Campisi… - The Journal of …, 2020 - ncbi.nlm.nih.gov
Since December 2019 the novel coronavirus SARS-CoV-2 has emerged as the cause of a
pandemic disease known as coronavirus disease 19 (COVID-19). 1 On February 21th 2020 …
pandemic disease known as coronavirus disease 19 (COVID-19). 1 On February 21th 2020 …
Real‐life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype
…, G Pelaia, S Nolasco, R Campisi… - Clinical & …, 2020 - Wiley Online Library
Background Anti‐interleukin‐5 (IL‐5) monoclonal antibodies can be used as add‐on biological
therapies in allergic and non‐allergic patients with severe eosinophilic asthma. However…
therapies in allergic and non‐allergic patients with severe eosinophilic asthma. However…
Utility of ultrasound assessment of diaphragmatic function before and after pulmonary rehabilitation in COPD patients
Background Pulmonary rehabilitation (PR) may improve respiratory symptoms and skeletal
muscle strength in patients with COPD. We aimed to evaluate changes in ultrasound (US) …
muscle strength in patients with COPD. We aimed to evaluate changes in ultrasound (US) …
[HTML][HTML] Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer
N Ciancio, MG Galasso, R Campisi, L Bivona… - Multidisciplinary …, 2012 - Springer
Background Overexpression of the tumor suppressor gene p53 and the marker for cellular
proliferation Ki67 in open lung biopsies are indicated as predictor factors of survival of …
proliferation Ki67 in open lung biopsies are indicated as predictor factors of survival of …
[HTML][HTML] Switching biological therapies in severe asthma
G Scioscia, S Nolasco, R Campisi, CMI Quarato… - International Journal of …, 2023 - mdpi.com
Currently, three classes of monoclonal antibodies targeting type 2 inflammation pathways
are available in Italy for the treatment of severe asthma: anti-IgE (Omalizumab), anti-IL-5/anti-IL…
are available in Italy for the treatment of severe asthma: anti-IgE (Omalizumab), anti-IL-5/anti-IL…